FDA Device Decisions, July 2025: Vagus Nerve Stimulation for Rheumatoid Arthritis, Four Original PMAs and One De Novo Grant
One of the four original PMAs FDA approved in July 2025 is the SetPoint System (P240039), an implanted stimulator on the left cervical vagus nerve for rheumatoid arthritis. It is for adults who had an inadequate response to biologic or targeted synthetic disease-modifying drugs, and it delivers one minute of stimulation once a day.
The month's single De Novo grant went to ArteraAI Prostate (DEN240068), software that analyzes prostate biopsy images to estimate 10-year risks of distant metastasis and prostate cancer-specific mortality.
Counting records held in RA Craft Database (decisions through August 31, 2026, tallied October 6), FDA cleared 281 510(k)s in July 2025, granted 1 De Novo request and approved 4 original PMAs. These counts have not been reconciled with FDA's own figures. The site holds 510(k), De Novo and PMA records from 2015 onward, and counts for past months can change as the data are updated.
Counts by pathway
July 2025 next to the previous month and the same month a year earlier, with records assigned to a month by FDA decision date.
| Pathway | July 2025 | June 2025 | July 2024 |
|---|---|---|---|
| 510(k) | 281 | 291 | 247 |
| De Novo | 1 | 3 | 5 |
| PMA (original) | 4 | 3 | 2 |
| PMA supplement | 195 | 216 | 193 |
Records held in RA Craft Database, decisions through August 31, 2026.
510(k) clearances were 10 fewer than in June but above July 2024 (247). There were 4 original PMAs.
The busiest product codes
July's 510(k)s spread across 176 product codes. GEX (powered laser surgical instrument) led with 8, followed by LLZ (system, image processing, radiological) and QIH (automated radiological image processing software) with 6 each. DZE (implant, endosseous, root-form), HRS (plate, fixation, bone), IYN (system, imaging, pulsed doppler, ultrasonic), MBI (fastener, fixation, nondegradable, soft tissue) and OWB (interventional fluoroscopic x-ray system) had 5 each. A single 510(k) can carry more than one product code, so per-code counts can add up to more than the number of submissions. If your code is on the list, enter it in the Product Code field on Search to see the records sorted by decision date.
De Novo: prognostic software for prostate cancer
July's single De Novo grant, Class II, with the classification name and regulation number from its Classification Order:
- ArteraAI Prostate (DEN240068, Artera, Inc.): Software algorithm device analyzing digital images for cancer prognosis (21 CFR 864.3755)
"21 CFR" refers to Title 21 of the Code of Federal Regulations, where FDA's regulations are codified.
It analyzes scanned hematoxylin and eosin (H&E) whole slide images from treatment-naive prostate core needle biopsies and reports 10-year risks of distant metastasis and prostate cancer-specific mortality, for men 55 and older without metastases who are candidates for curative-intent management. Physicians use it alongside other clinicopathological factors.
Original PMAs: four approvals
- Oncomine Dx Express Test (P240040, Life Technologies Corporation): a next-generation sequencing tumor test, including a companion diagnostic claim to identify non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertions for sunvozertinib (product code PQP)
- TOUCH® CMC 1 Prosthesis (P240020, Keri Medical SA): a total joint replacement for osteoarthritis at the base of the thumb (first carpometacarpal joint) (SFA)
- Quest Diagnostics AAVrh74 Antibody ELISA CDx (P250002, Quest Diagnostics Nichols Institute): measures antibodies to the AAVrh74 capsid to determine eligibility for gene therapy (QWQ)
- SetPoint System (P240039, SetPoint Medical): an implanted vagus nerve stimulator for rheumatoid arthritis (SFJ)
July also brought 195 PMA supplements, which cover changes to already approved PMA devices among other things.
Three devices worth a closer read
1. SetPoint System (P240039, PMA). The implant stimulates the left cervical vagus nerve for one minute once a day and is recharged wirelessly with a neck-worn charger. According to the Summary of Safety and Effectiveness Data (SSED) that FDA published with the approval, in the double-blind, sham-controlled RESET-RA trial, 35.2% of treated patients reached ACR20 (at least 20% improvement on the American College of Rheumatology criteria) at week 12 versus 24.2% with sham. The device received Breakthrough Device designation in 2024. Conditions of approval include a registry-based post-approval study of implanted patients.
2. ArteraAI Prostate (DEN240068, De Novo). Two special controls, labeling and design verification and validation, carry most of the weight. They require a description of the datasets used to train, tune and test the algorithm and their representativeness (multiple sites, demographics, challenging cases), plus clinical validation on an independent dataset with subgroup analysis. For image-analysis software, the dataset requirements are spelled out in detail.
3. Quest Diagnostics AAVrh74 Antibody ELISA CDx (P250002, PMA). The assay measures antibodies to the AAVrh74 vector: a titer below 1:400 means the patient may be eligible for the gene therapy, 1:400 or above means ineligible. According to the SSED, it selects patients with Duchenne muscular dystrophy for a gene therapy. The approval order limits sale and distribution to Quest Diagnostics Nichols Institute. The device received Breakthrough Device designation in 2023.
Compare the three devices
Open P240039, DEN240068 and P250002, star (☆) each one, tick "Compare" on all three in My Workspace and press "3 selected for comparison". The comparison table puts their Indications for Use side by side. Before relying on any of this, open "FDA Record" and "Summary PDF" on each record and read the source.
Note: months are assigned by FDA decision date, and counts can change as the data are updated each month.
RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.
← All articles